Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition

References

• Kasakovski D, Skrygan M, Gambichler T, Susok L. Advances in targeting cutaneous melanoma. Cancers. 2021;13(9):2090. doi:10.3390/cancers13092090
   PubMed Web of Science ®Google Scholar
• Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2(1):zcaa002. doi:10.1093/narcan/zcaa002
   PubMedGoogle Scholar
• Xu H, Wen Y, Chen S, Zhu L, Feng R, Song Z. Paclitaxel skin delivery by micelles-embedded carbopol 940 hydrogel for local therapy of melanoma. Int J Pharm. 2020;587:119626. doi:10.1016/j.ijpharm.2020.119626
   PubMedGoogle Scholar
• Kim TK, Vandsemb EN, Herbst RS, Chen L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat Rev Drug Discov. 2022;21(7):529–540. doi:10.1038/s41573-022-00493-5
   PubMed Web of Science ®Google Scholar
• Rigon RB, Oyafuso MH, Fujimura AT, et al. Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review. Biomed Res Int. 2015;2015:841817. doi:10.1155/2015/841817
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Goldfarb SB, Markova A, et al. Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer. Breast Cancer Res Treat. 2022;194(1):57–64. doi:10.1007/s10549-022-06584-6
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–2788. doi:10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Sharma N, Schmidt CM, Jain S, et al. S2 Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac). Am J Gastroenterol. 2021;116:S1–S2.
   PubMed Web of Science ®Google Scholar
• Verco S, Maulhardt H, Baltezor M, et al. Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies. Drug Deliv Transl Res. 2021;11(5):1806–1817. doi:10.1007/s13346-020-00868-4
   PubMed Web of Science ®Google Scholar
• Kates M, Mansour A, Lamm DL, et al. Phase 1/2 trial results of a large surface area microparticle docetaxel for the treatment of high-risk non-muscle invasive bladder cancer. J Urol. 2022;208(4):821–829. doi:10.1097/JU.0000000000002778
   PubMed Web of Science ®Google Scholar
• Maulhardt H, Verco S, Baltezor M, Marin A, diZerega G. Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies. Drug Deliv Transl Res. 2022;2023:1.
   Google Scholar
• Sharma NR, Lo SK, Hendifar A, et al. Response of locally advanced pancreatic cancer to intratumoral injection of large surface area microparticle paclitaxel: initial report of safety and clinical outcome. Pancreas. 2023;52(3):e179–e187. doi:10.1097/MPA.0000000000002236
   PubMedGoogle Scholar
• Maulhardt HA, Marin AM, diZerega GS. Intratumoral submicron particle docetaxel inhibits syngeneic renca renal cancer growth and increases CD4+, CD8+, and treg levels in peripheral blood. Invest New Drugs. 2020;38(5):1618–1626. doi:10.1007/s10637-020-00922-5
   PubMed Web of Science ®Google Scholar
• Verco S, Maulhardt H, Marin A, Verco A. Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies. J Clin Oncol in Press. 2023;41(16_suppl):e15187–e15187. doi:10.1200/JCO.2023.41.16_suppl.e15187
   Web of Science ®Google Scholar
• Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18(9):558–576. doi:10.1038/s41571-021-00507-y
   PubMed Web of Science ®Google Scholar
• Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017; 28(suppl_12):xii33–xii43.
   PubMedGoogle Scholar
• Moe A, Liow E, Redfern A, et al. A Phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol. BJU Int. 2021;128 Suppl 1:9–17. doi:10.1111/bju.15365
   PubMed Web of Science ®Google Scholar
• Rouanne M, Bajorin DF, Hannan R, et al. Rationale and outcomes for neoadjuvant immunotherapy in urothelial carcinoma of the bladder. Eur Urol Oncol. 2020;3(6):728–738. doi:10.1016/j.euo.2020.06.009
   PubMed Web of Science ®Google Scholar
• Schulz GB, Black PC. Combination therapies involving checkpoint-inhibitors for treatment of urothelial carcinoma: a narrative review. Transl Androl Urol. 2021;10(10):4014–4021. doi:10.21037/tau-20-1177
   PubMed Web of Science ®Google Scholar
• Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother. 2000;49(4–5):181–185. doi:10.1007/s002620000122
   PubMed Web of Science ®Google Scholar
• Soliman HH. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther. 2017;10:101–112. doi:10.2147/OTT.S122974
   PubMed Web of Science ®Google Scholar
• Javeed A, Ashraf M, Riaz A, Ghafoor A, Afzal S, Mukhtar MM. Paclitaxel and immune system. Eur J Pharm Sci. 2009;38(4):283–290. doi:10.1016/j.ejps.2009.08.009
   PubMed Web of Science ®Google Scholar
• Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9(11):913–927. doi:10.2217/imt-2017-0052
   PubMed Web of Science ®Google Scholar
• Conway EM, Pikor LA, Kung SH, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193(2):116–130. doi:10.1164/rccm.201508-1545CI
   PubMed Web of Science ®Google Scholar
• Demaria S, Volm MD, Shapiro RL, et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res. 2001;7(10):3025–3030.
   PubMed Web of Science ®Google Scholar
• Moschetta M, Pretto F, Berndt A, et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 2012;72(7):1814–1824. doi:10.1158/0008-5472.CAN-11-1919
   PubMed Web of Science ®Google Scholar
• Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res. 2012;18(15):4092–4103. doi:10.1158/1078-0432.CCR-12-0282
   PubMed Web of Science ®Google Scholar
• Vicari AP, Luu R, Zhang N, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother. 2009;58(4):615–628. doi:10.1007/s00262-008-0586-2
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62(2):203–216. doi:10.1007/s00262-012-1388-0
   PubMed Web of Science ®Google Scholar
• Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta. 2016;1865(2):228–236. doi:10.1016/j.bbcan.2016.03.003
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215–233. doi:10.1038/nrd3626
   PubMed Web of Science ®Google Scholar
• Champiat S, Tselikas L, Farhane S, et al. Intratumoral immunotherapy: from trial design to clinical practice. Clin Cancer Res. 2021;27(3):665–679. doi:10.1158/1078-0432.CCR-20-0473
   PubMed Web of Science ®Google Scholar
• Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72(2):430–439. doi:10.1158/0008-5472.CAN-11-1782
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018;39(8):644–655. doi:10.1016/j.it.2018.06.001
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104. doi:10.1186/s13045-018-0647-8
   PubMed Web of Science ®Google Scholar
• Williamson SK, Johnson GA, Maulhardt HA, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax(R)) in patients with peritoneal malignancies. Cancer Chemother Pharm. 2015;75(5):1075–1087. doi:10.1007/s00280-015-2737-4
   PubMed Web of Science ®Google Scholar
• Mullany S, Miller D, Robison K, et al. Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery. Gynecol Oncol Rep. 2020;34(100627):100627. doi:10.1016/j.gore.2020.100627
   PubMedGoogle Scholar
• Othman M, Patel K, Krishna S, et al. Early Phase Trial of Intracystic Injection of Large Surface Area Microparticle Paclitaxel for the Treatment of Mucinous Pancreatic Cysts. Endosc Int Open. 2022; 10(12):1.
   Web of Science ®Google Scholar
• Wilson MA, Schuchter LM. Chemotherapy for melanoma. Cancer Treat Res. 2016;167:209–229.
   PubMedGoogle Scholar